Vincerx Pharma, Inc.

NasdaqCM:VINC Stock Report

Market Cap: US$8.6m

Vincerx Pharma Valuation

Is VINC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VINC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VINC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VINC's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for VINC?

Key metric: As VINC is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for VINC. This is calculated by dividing VINC's market cap by their current book value.
What is VINC's PB Ratio?
PB Ratio0.9x
BookUS$9.11m
Market CapUS$8.59m

Price to Book Ratio vs Peers

How does VINC's PB Ratio compare to its peers?

The above table shows the PB ratio for VINC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.3x
ENSC Ensysce Biosciences
1.2x102.6%US$11.6m
SNGX Soligenix
1.4x-12.1%US$8.4m
FBRX Forte Biosciences
2.5xn/aUS$22.8m
EGRX Eagle Pharmaceuticals
0.05xn/aUS$11.7m
VINC Vincerx Pharma
0.9x-15.6%US$8.6m

Price-To-Book vs Peers: VINC is good value based on its Price-To-Book Ratio (0.9x) compared to the peer average (1.3x).


Price to Book Ratio vs Industry

How does VINC's PB Ratio compare vs other companies in the US Biotechs Industry?

60 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$550.38m
IMAB I-Mab
0.4x1.8%US$78.16m
ACET Adicet Bio
0.4x6.7%US$75.31m
MGX Metagenomi
0.3x-23.2%US$68.11m
VINC 0.9xIndustry Avg. 1.9xNo. of Companies82PB01.63.24.86.48+
60 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: VINC is good value based on its Price-To-Book Ratio (0.9x) compared to the US Biotechs industry average (1.8x).


Price to Book Ratio vs Fair Ratio

What is VINC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VINC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate VINC's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VINC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.25
US$6.00
+2,281.0%
66.7%US$10.00US$2.00n/a2
Nov ’25US$0.36
US$6.00
+1,543.8%
66.7%US$10.00US$2.00n/a2
Oct ’25US$0.69
US$7.00
+921.7%
42.9%US$10.00US$4.00n/a2
Sep ’25US$0.82
US$7.00
+753.7%
42.9%US$10.00US$4.00n/a2
Aug ’25US$0.62
US$7.00
+1,027.4%
42.9%US$10.00US$4.00n/a2
Jul ’25US$0.76
US$7.00
+821.9%
42.9%US$10.00US$4.00n/a2
Jun ’25US$0.63
US$7.00
+1,009.4%
42.9%US$10.00US$4.00n/a2
May ’25US$0.89
US$9.00
+912.1%
11.1%US$10.00US$8.00n/a2
Apr ’25US$5.85
US$9.00
+53.8%
11.1%US$10.00US$8.00n/a2
Mar ’25US$4.33
US$7.00
+61.7%
42.9%US$10.00US$4.00n/a2
Feb ’25US$1.19
US$7.00
+488.2%
42.9%US$10.00US$4.00n/a2
Jan ’25US$1.18
US$7.00
+493.2%
42.9%US$10.00US$4.00n/a2
Dec ’24US$0.70
US$7.00
+900.0%
42.9%US$10.00US$4.00n/a2
Nov ’24US$0.91
US$6.33
+599.8%
41.4%US$10.00US$4.00US$0.363
Oct ’24US$1.01
US$6.33
+527.1%
41.4%US$10.00US$4.00US$0.693
Sep ’24US$0.71
US$6.33
+789.9%
41.4%US$10.00US$4.00US$0.823
Aug ’24US$1.02
US$6.67
+553.6%
35.4%US$10.00US$5.00US$0.623
Jul ’24US$1.30
US$6.67
+412.8%
35.4%US$10.00US$5.00US$0.763
Jun ’24US$1.85
US$6.67
+260.4%
35.4%US$10.00US$5.00US$0.633
May ’24US$1.47
US$6.67
+353.5%
35.4%US$10.00US$5.00US$0.893
Apr ’24US$1.04
US$9.75
+837.5%
58.6%US$19.00US$5.00US$5.854
Mar ’24US$1.09
US$9.75
+794.5%
58.6%US$19.00US$5.00US$4.334
Feb ’24US$1.51
US$8.40
+456.3%
68.8%US$19.00US$3.00US$1.195
Jan ’24US$1.02
US$8.40
+723.5%
68.8%US$19.00US$3.00US$1.185
Dec ’23US$0.71
US$12.40
+1,646.5%
84.7%US$30.00US$3.00US$0.705
Nov ’23US$1.07
US$13.00
+1,115.0%
77.4%US$30.00US$4.00US$0.915

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies